These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 9765662)

  • 1. [Thrombin and its pharmacologic regulation].
    Guillin MC
    Presse Med; 1998 Jun; 27 Suppl 2():22-7. PubMed ID: 9765662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies for inhibiting the effects of thrombin.
    Harker LA
    Blood Coagul Fibrinolysis; 1994 Jan; 5 Suppl 1():S47-58; discussion S59-64. PubMed ID: 8186356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithrombotic effects of synthetic peptides targeting various functional domains of thrombin.
    Kelly AB; Maraganore JM; Bourdon P; Hanson SR; Harker LA
    Proc Natl Acad Sci U S A; 1992 Jul; 89(13):6040-4. PubMed ID: 1385867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A player of many parts: the spotlight falls on thrombin's structure.
    Stubbs MT; Bode W
    Thromb Res; 1993 Jan; 69(1):1-58. PubMed ID: 8465268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of thrombus growth by antithrombin III-dependent and two direct thrombin inhibitors in rabbits: implications for antithrombotic therapy.
    Brill-Edwards P; Van Ryn-McKenna J; Cai L; Ofosu FA; Buchanan MR
    Thromb Haemost; 1992 Oct; 68(4):424-7. PubMed ID: 1448774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of thrombin active site and exosite inhibitors and heparin in experimental models of arterial and venous thrombosis and bleeding.
    Schumacher WA; Steinbacher TE; Heran CL; Seiler SM; Michel IM; Ogletree ML
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1237-42. PubMed ID: 8263785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experimental thrombosis on a collagen coated arterioarterial shunt in rats: a pharmacological model to study antithrombotic agents inhibiting thrombin formation and platelet deposition.
    Freund M; Mantz F; Nicolini P; Gachet C; Mulvihill J; Meyer L; Beretz A; Cazenave JP
    Thromb Haemost; 1993 May; 69(5):515-21. PubMed ID: 8322274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modes and consequences of thrombin's interaction with fibrin.
    Fredenburgh JC; Stafford AR; Pospisil CH; Weitz JI
    Biophys Chem; 2004 Dec; 112(2-3):277-84. PubMed ID: 15572259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic effect of aptamers that inhibit exosites 1 and 2 on thrombin.
    Nimjee SM; Oney S; Volovyk Z; Bompiani KM; Long SB; Hoffman M; Sullenger BA
    RNA; 2009 Dec; 15(12):2105-11. PubMed ID: 19846574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of thrombin's clotting activity by synthetic peptide segments of its inhibitors and substrates.
    Hortin GL; Benutto BM
    Biochem Biophys Res Commun; 1990 Jun; 169(2):437-42. PubMed ID: 2357214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
    Hérault JP; Bernat A; Gaich C; Herbert M
    Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of antithrombin III-independent thrombin inhibitors and heparin on fibrin accretion onto fibrin-coated polyethylene.
    Rubens FD; Weitz JI; Brash JL; Kinlough-Rathbone RL
    Thromb Haemost; 1993 Feb; 69(2):130-4. PubMed ID: 8456425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct thrombin inhibitors.
    Weitz JI; Crowther M
    Thromb Res; 2002 May; 106(3):V275-84. PubMed ID: 12356489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet aggregation: involvement of thrombin and fibrin(ogen).
    Lisman T; Weeterings C; de Groot PG
    Front Biosci; 2005 Sep; 10():2504-17. PubMed ID: 15970513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The dual role of thrombin's anion-binding exosite-I in the recognition and cleavage of the protease-activated receptor 1.
    Myles T; Le Bonniec BF; Stone SR
    Eur J Biochem; 2001 Jan; 268(1):70-7. PubMed ID: 11121104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antithrombin agents as anticoagulants and antithrombotics: implications in drug development.
    Fareed J; Callas D; Hoppensteadt DA; Lewis BE; Bick RL; Walenga JM
    Semin Hematol; 1999 Jan; 36(1 Suppl 1):42-56. PubMed ID: 9930564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Probing the Dynamics of Clot-Bound Thrombin at Venous Shear Rates.
    Haynes LM; Orfeo T; Mann KG; Everse SJ; Brummel-Ziedins KE
    Biophys J; 2017 Apr; 112(8):1634-1644. PubMed ID: 28445754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bivalirudin: a new promising direct antithrombin.
    Bhambhani A; Meier B
    Indian Heart J; 2007; 59(3):288-94. PubMed ID: 19124943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ClfA(221-550), a fibrinogen-binding segment of Staphylococcus aureus clumping factor A, disrupts fibrinogen function.
    Liu CZ; Shih MH; Tsai PJ
    Thromb Haemost; 2005 Aug; 94(2):286-94. PubMed ID: 16113817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bothrojaracin: a potent two-site-directed thrombin inhibitor.
    Arocas V; Zingali RB; Guillin MC; Bon C; Jandrot-Perrus M
    Biochemistry; 1996 Jul; 35(28):9083-9. PubMed ID: 8703912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.